Andere Sprachen Tonix Pharmaceuticals Nasdaq

Aktien

A3DL8Q

US8902608624

TNXP

Schlusskurs Nasdaq Andere Börsenplätze 00:00:00 05.02.2024			% 5 Tage	% 1. Jan.
0,3222 ^USD	-2,36 %		+2,32 %	-20,05 %

01.04.	Tonix Pharmaceuticals Holding Corp. meldet Ergebnis für das vierte Quartal bis zum 31. Dezember 2023	CI
01.04.	Tonix Pharmaceuticals Holding Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase	24.04.
Tonix Pharmaceuticals : Investor Presentation April 2024	19.04.
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	09.04.
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01.04.
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	01.04.
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble	28.03.
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering	28.03.
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome	25.03.
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome	25.03.
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting	21.03.
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting	21.03.
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia	20.03.
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024	19.03.
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	13.03.
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring	12.03.
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial	11.03.
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia	11.03.
Tonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia	07.03.
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy	07.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tonix Pharmaceuticals Nasdaq

Aktien

A3DL8Q

US8902608624

TNXP

Andere Sprachen

Filter